Clinical Trial Update: A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating survodutide (BI 456906) for weight loss in Chinese adults living with overweight or obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Survodutide (BI456906)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Obesity, Overweight | Phase 3 | Status: COMPLETED